PDA

View Full Version : Halozyme Announces Roche Doses First Patient In Phase 3 Clinical Trial With Subcutane

News
10-22-2009, 08:10 PM
Halozyme Therapeutics, Inc. (Nasdaq:HALO) and Roche announced dosing of the first patient in a Phase 3 registration trial using Enhanze? technology (rHuPH20, recombinant human hyaluronidase) in a subcutaneous formulation with Roche's anticancer biologic, Herceptin (trastuzumab).

More... (http://www.medicalnewstoday.com/articles/168358.php)